BL
XPH icon

Balentine LLC’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Balentine LLC’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,635
Closed -$71K – 535
2017
Q4 		$71K Buy
+1,635
New +$69.5K 0.01% 235

Other funds holding XPH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
AL
Arnhold LLC New York $1.36B AUM 53.52% 1-Year Est. Return

Balentine LLC's XPH Position: Q1 2018 in Review

Balentine LLC sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2018, closing a stake of 1,635 shares — an estimated $71K sold.

Balentine LLC first reported a position in XPH in Q4 2017 and held it in 1 quarter. The position peaked at $71K in Q4 2017. 75 funds tracked by Wall St. Rank hold XPH as of Q1 2018.

  • Balentine LLC reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2018 after selling out during the quarter.
  • Balentine LLC sold 1,635 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2018, an estimated $71K.
  • Balentine LLC first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2017 and held it in 1 quarter.
  • Balentine LLC's State Street SPDR S&P Pharmaceuticals ETF position peaked at $71K in Q4 2017.
  • 75 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2018.

Based on Balentine LLC's 13F filing for Q1 2018, filed 16 May 2018.